Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086410 · ClinicalTrials.gov registry record · Phase 3
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT01086410 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 185 participants.
The verdict
NCT01086410, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
Interventions
- DRUG Placebo Oral Capsule
- DRUG Placebo Inhalation Powder
- DRUG Fluticasone Furoate/GW642444 Inhalation Powder
- DRUG Prednisolone Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01086410
The ClinicalTrials.gov registry entry for NCT01086410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Oral Capsule is the first listed.
NCT01086410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01086410 about?
NCT01086410 is a clinical study titled "Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis". The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
What is the current status of trial NCT01086410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2010-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01086410?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Placebo Inhalation Powder (DRUG), Fluticasone Furoate/GW642444 Inhalation Powder (DRUG), Prednisolone Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT01086410?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.